Cooperative Study of Factor VIII Inhibitors
Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Oct 27, 1999
Trial Information
Current as of March 27, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
Despite major advances in the treatment of patients with hemophilia, a serious remaining challenge was presented by the occurrence of circulating inhibitors to Factor VIII. Because of lack of information on the natural course of patients with Factor VIII inhibitors, the relative efficacy of various modes of therapy was not established. The Division of Blood Diseases and Resources decided to sponsor a clinical investigation which would evaluate populations of hemophilia patients for Factor VIII inhibitors, follow up these patients to provide information on the natural history of...
Gender
MALE
Eligibility criteria
- • Males with hemophilia, not stratified as to ethnic group.
Trial Officials
Louis Aledort
Icahn School of Medicine at Mount Sinai
J. Edson
University of Minnesota
M. Eyster
Milton S. Hershey Medical Center
Scott Goodnight
University of Oregon Health Sciences Center
William Hathaway
University of Colorado Medical Center
Jack Lazerson
Milwaukee Children's Hospital
Peter Levine
Memorial hospital
Jeanne Lusher
Wayne State University
Campbell McMillan
University of North Carolina
Sandor Shapiro
Thomas Jefferson University
About National Heart, Lung, And Blood Institute (Nhlbi)
The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials